| Literature DB >> 34473477 |
Siddharth Sourabh Sahu1, Sara Cavallaro2, Petra Hååg3, Ábel Nagy4, Amelie Eriksson Karlström4, Rolf Lewensohn3,5, Kristina Viktorsson3, Jan Linnros2, Apurba Dev1,2.
Abstract
We present an approach to improve the detection sensitivity of a streaming current-based biosensor for membrane protein profiling of small extracellular vesicles (sEVs). The experimental approach, supported by theoretical investigation, exploits electrostatic charge contrast between the sensor surface and target analytes to enhance the detection sensitivity. We first demonstrate the feasibility of the approach using different chemical functionalization schemes to modulate the zeta potential of the sensor surface in a range -16.0 to -32.8 mV. Thereafter, we examine the sensitivity of the sensor surface across this range of zeta potential to determine the optimal functionalization scheme. The limit of detection (LOD) varied by 2 orders of magnitude across this range, reaching a value of 4.9 × 106 particles/mL for the best performing surface for CD9. We then used the optimized surface to profile CD9, EGFR, and PD-L1 surface proteins of sEVs derived from non-small cell lung cancer (NSCLC) cell-line H1975, before and after treatment with EGFR tyrosine kinase inhibitors, as well as sEVs derived from pleural effusion fluid of NSCLC adenocarcinoma patients. Our results show the feasibility to monitor CD9, EGFR, and PD-L1 expression on the sEV surface, illustrating a good prospect of the method for clinical application.Entities:
Keywords: charge modulation; electrokinetic method; enhanced sensitivity; extracellular vesicles; lung cancer; streaming current; surface proteins; treatment monitoring
Mesh:
Substances:
Year: 2021 PMID: 34473477 PMCID: PMC8447189 DOI: 10.1021/acsami.1c13192
Source DB: PubMed Journal: ACS Appl Mater Interfaces ISSN: 1944-8244 Impact factor: 9.229
Figure 1Schematic diagrams of the various functionalization methods used: (a) APTES-GA: the capillary surface was coated with a self-assembled monolayer of APTES, which was linked to the capture antibody via a glutaraldehyde linker. (b) PPB-avidin/streptavidin: the capillary surface was coated with a layer of a PLL-PEG copolymer conjugated with biotin, which was then linked to the capture antibody via an avidin or streptavidin linker. The sEVs were then in both cases detected via the capture antibody. The blocking agents used were (a) casein solution and (b) pluronic F108. Panel (c) shows the experimental setup used in the electrokinetic measurements.
Figure 2(a) Simulations demonstrating the possibility to enhance the signal by modulating the surface charge, ζ*. The signal was simulated for sEVs with ζp = −30 mV and ζ* = −10, −20, and −30 mV. (b) Initial baselines, ζ*, measured for three functionalization methods used: APTES-GA, PPB-avidin, and PPB-streptavidin. (c) Comparison of the signal (Δζ*) obtained on the differently functionalized surface when targeting the extracellular domain of the CD9 membrane protein on sEVs isolated from cell culture media of H1975 cells. The negative control involved mouse IgG1 isotype control antibodies instead of anti-CD9 antibodies. APTES-GA, PPB, and PPB-avidin functionalized surfaces were also studied with AFM (in PBS buffer) to compare their surface roughness. The AFM images for these three surfaces are shown in panels (d)–(f), respectively. The rms roughness (δ) is indicated below each AFM image. The APTES-GA surface shows considerably higher roughness in comparison to the PPB and PPB-avidin surface.
Figure 3(a) Concentration-dependent response of the sensor when probed with sEVs from the cell culture media of untreated EGFR-mutant NSCLC H1975 cells using biotinylated anti-CD9 antibodies via PPB-based functionalization. The NTA curves of sEVs are shown in Figure S2. The expressions of CD9 and EGFR in these sEVs are previously reported.[30] (b) Surface expression levels of CD9, EGFR, and PD-L1 for sEVs from cell culture media of H1975 cells prior and post treatments with 1 μM erlotinib or 0.1 μM osimertinib for 48 h. The cell morphology and cell viability of H1975 upon tyrosine kinase inhibitor (TKI) treatment are shown in Figure S3a,b and CD9 expression from Western blot analyses is presented in Figure S3c. (c) sEV samples isolated from PE-fluid of two NSCLC adenocarcinoma patients PE002 and PE011 using the same capturing and affinity reagents as in (b). The control measurements were performed using IgG1 isotype control antibodies.
Details of H1975 and PE-Fluid Isolated sEVs for Validating the Improved Method for Profiling the Membrane Proteins of sEVsa
| sample | treatment | tumor stage | genomic alteration | feature |
|---|---|---|---|---|
| H1975 cell line | untreated | EGFR exon 21, L858R, exon 20 T790M | ||
| erlotinib | resistant[ | |||
| osimertinib | responsive (see | |||
| PE002 | ALK TKI crizotinib | T2aN0M1a | EML4-ALK variant 3 (a/b) | responsive |
| PE011 | EGFR-TKI erlotinib | T4N2M1a | EGFR exon 21, L858R | progressive |
The cell line-derived sEVs were used to monitor the effects of TKI treatment, whereas plural effusion (PE) samples were used to determine the possibility to analyze sEVs from the complex patients’ sample.
ζi* and σeff of Surfaces at Various Stages of Functionalizationa
| surface | ζi* (mV) | σeff (10–3 e/nm2) |
|---|---|---|
| bare silica | –68.6 | –5.2 |
| GA-APTES | –32.5 | –2.0 |
| GA-APTES-anti-CD9 | –32.8 | –2.0 |
| PPB | –26.3 | –1.6 |
| PPB-avidin | –14.1 | –0.8 |
| PPB-avidin-anti-CD9 | –16.0 | –0.9 |
| PPB-streptavidin | –20.7 | –1.2 |
| PPB-streptavidin-anti-CD9 | –23.3 | –1.4 |
Clearly, PPB-avidin leads to the least negatively charged surface among the three functionalization schemes tested.